{"id":68093,"date":"2026-06-12T20:26:43","date_gmt":"2026-06-12T12:26:43","guid":{"rendered":"https:\/\/flcube.com\/?p=68093"},"modified":"2026-06-12T20:26:44","modified_gmt":"2026-06-12T12:26:44","slug":"shouyao-holdings-secures-nmpa-approval-for-second-generation-alk-inhibitor-ct-707-as-first-line-treatment-for-alk-positive-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68093","title":{"rendered":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shouyao Holdings (Beijing) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688197:SHA\">SHA: 688197<\/a>), a Beijing-based pharmaceutical company, announced it has received <strong>marketing approval from the National Medical Products Administration (NMPA)<\/strong> for its <strong>CT-707<\/strong>, a <strong>second-generation ALK inhibitor<\/strong>. The approval allows CT-707 to be used in patients with <strong>ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> who have not previously received treatment with an <strong>anaplastic lymphoma kinase (ALK) inhibitor<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td>CT-707<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Second-generation ALK inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>ALK-positive locally advanced or metastatic NSCLC<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Treatment-na\u00efve (no prior ALK inhibitor therapy)<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Pivotal Phase III clinical study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-results-phase-iii-study\" class=\"wp-block-heading\">Clinical Trial Results \u2013 Phase III Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Efficacy Measure<\/th><th>CT-707 Performance<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression-Free Survival (PFS)<\/strong><\/td><td>Clinically meaningful improvement<\/td><td>Primary endpoint met<\/td><\/tr><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td>Statistically significant benefit<\/td><td>Key secondary endpoint<\/td><\/tr><tr><td><strong>Duration of Response (DoR)<\/strong><\/td><td>Extended response duration<\/td><td>Demonstrates sustained efficacy<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable overall safety and tolerability<\/td><td>Manageable adverse events<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Pivotal Phase III, first-line setting<\/td><td>Head-to-head vs. standard of care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The complete Phase III data demonstrates that CT-707 provides <strong>clinically meaningful benefits across all key efficacy measures<\/strong> in the first-line treatment setting for ALK-positive NSCLC.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-competitive-positioning\" class=\"wp-block-heading\">Drug Profile &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> CT-707 \u2013 <strong>second-generation ALK inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target Population:<\/strong> <strong>ALK-positive NSCLC<\/strong> patients (approximately 3-7% of all NSCLC cases)<\/li>\n\n\n\n<li><strong>Treatment Setting:<\/strong> <strong>First-line therapy<\/strong> for treatment-na\u00efve patients<\/li>\n\n\n\n<li><strong>Generational Advantage:<\/strong> Second-generation inhibitors typically offer improved CNS penetration and activity against resistance mutations compared to first-generation agents like crizotinib<\/li>\n\n\n\n<li><strong>Market Entry:<\/strong> Positions Shouyao Holdings in the competitive ALK inhibitor landscape alongside established players<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Drug<\/th><th>Generation<\/th><th>Market Status in China<\/th><\/tr><\/thead><tbody><tr><td><strong>Pfizer<\/strong><\/td><td>Crizotinib<\/td><td>First-generation<\/td><td>Approved, generic versions available<\/td><\/tr><tr><td><strong>Roche<\/strong><\/td><td>Alectinib<\/td><td>Second-generation<\/td><td>Approved, premium pricing<\/td><\/tr><tr><td><strong>Novartis<\/strong><\/td><td>Ceritinib<\/td><td>Second-generation<\/td><td>Approved<\/td><\/tr><tr><td><strong>Takeda<\/strong><\/td><td>Brigatinib<\/td><td>Second-generation<\/td><td>Approved<\/td><\/tr><tr><td><strong>Shouyao Holdings<\/strong><\/td><td><strong>CT-707<\/strong><\/td><td><strong>Second-generation<\/strong><\/td><td><strong>Newly approved<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Market Size:<\/strong> Lung cancer represents the <strong>most common cancer globally<\/strong>, with NSCLC accounting for approximately <strong>85% of cases<\/strong><\/li>\n\n\n\n<li><strong>ALK-Positive Subset:<\/strong> Represents <strong>3-7% of NSCLC patients<\/strong>, translating to thousands of eligible patients annually in China<\/li>\n\n\n\n<li><strong>Treatment Paradigm:<\/strong> Second-generation ALK inhibitors have become the preferred first-line option due to superior efficacy and CNS activity<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Domestic development provides potential cost advantages over imported branded therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic Innovation:<\/strong> Represents another milestone in China&#8217;s growing capability to develop targeted oncology therapies<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Local manufacturing and development may facilitate broader patient access through favorable pricing and reimbursement negotiations<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Specific efficacy and safety advantages over existing second-generation ALK inhibitors will determine market positioning<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success with CT-707 validates Shouyao Holdings&#8217; oncology drug development capabilities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial potential, market opportunities, and competitive positioning. Actual results may differ due to risks including market adoption, pricing pressures, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68094,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,15,1173,344],"class_list":["post-68093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-product-approvals","tag-sha-688197","tag-shouyao-holdings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68093\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC\" \/>\n<meta property=\"og:description\" content=\"Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68093\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T12:26:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T12:26:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC\",\"datePublished\":\"2026-06-12T12:26:43+00:00\",\"dateModified\":\"2026-06-12T12:26:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201-1.webp\",\"keywords\":[\"Cancer\",\"Product approvals\",\"SHA: 688197\",\"Shouyao Holdings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68093#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68093\",\"name\":\"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201-1.webp\",\"datePublished\":\"2026-06-12T12:26:43+00:00\",\"dateModified\":\"2026-06-12T12:26:44+00:00\",\"description\":\"Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68093\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1201-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68093#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68093","og_locale":"en_US","og_type":"article","og_title":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC","og_description":"Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.","og_url":"https:\/\/flcube.com\/?p=68093","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T12:26:43+00:00","article_modified_time":"2026-06-12T12:26:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68093#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68093"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC","datePublished":"2026-06-12T12:26:43+00:00","dateModified":"2026-06-12T12:26:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68093"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp","keywords":["Cancer","Product approvals","SHA: 688197","Shouyao Holdings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68093#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68093","url":"https:\/\/flcube.com\/?p=68093","name":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68093#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp","datePublished":"2026-06-12T12:26:43+00:00","dateModified":"2026-06-12T12:26:44+00:00","description":"Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197), a Beijing-based pharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for its CT-707, a second-generation ALK inhibitor. The approval allows CT-707 to be used in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received treatment with an anaplastic lymphoma kinase (ALK) inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68093#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68093"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68093#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp","width":1080,"height":608,"caption":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68093#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1201-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68093"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68093\/revisions"}],"predecessor-version":[{"id":68095,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68093\/revisions\/68095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68094"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}